# A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC

> **NCT02246049** · PHASE2 · COMPLETED · sponsor: **EPS Corporation** · enrollment: 69 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** 5-fluorouracil
- **DRUG:** Irinotecan hydrochloride
- **DRUG:** Leucovorin calcium
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT02246049
- **Lead sponsor:** EPS Corporation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2017-02
- **Final completion:** 2017-02
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2017-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02246049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02246049, "A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02246049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*